Logo

Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Share this

Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Shots:

  • Genentech reports the new data for Enspryng on reducing relapse severity in the treatment of neuromyelitis optical spectrum disorder (NMOSD)- to be presented at MSVirtual2020.
  • In a pos-thoc analysis- 79% reduction in relapse severity by vs PBO (19% vs 35%) in P-III SAkura studies. Pooled data from Sakura OLE studies support the continued effect of Enspryng reducing the risk of relapse in the longer term by 51% and showed more effect in AQP4-IgG seropositive patients i.e. 66% reduction in risk of relapse
  • Enspryng is the 1st and only FDA-approved SC- self-administered medicine for NMOSD and the 1st medicine for NMOSD which targets the IL-6 receptor- approved in Canada- Japan- Switzerland- and the US. Additionally- it has received the US FDA’s BT designation for NMOSD in Dec’2018

­ Ref: Genentech | Image: Life Science Review

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions